Sugi Predict

Sugi Predict / Compounds / SCHEMBL837014

SCHEMBL837014

SCHEMBL837014

N[C@H](Cc1ccc(-c2ccc(C[C@@H](N)C(=O)O)cc2)cc1)C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 3/20 0.74
▸ PTGS1 P23219 3/20 0.73
▸ ALPI P09923 1/20 0.73
▸ PKM P14618 1/20 0.73
▸ XIAP P98170 1/20 0.73
▸ HIF1A Q16665 4/20 0.61
▸ ALOX15 P16050 3/20 0.61
▸ KDM4E B2RXH2 2/20 0.61
▸ TDP1 Q9NUW8 2/20 0.61
▸ HSD17B10 Q99714 2/20 0.61
▸ USP2 O75604 1/20 0.61
▸ EGFR P00533 1/20 0.61
▸ LCK P06239 1/20 0.61
▸ FYN P06241 1/20 0.61
▸ ADORA3 P0DMS8 1/20 0.61
▸ HTR2A P28223 1/20 0.61
▸ PTGS2 P35354 1/20 0.61
▸ RECQL P46063 1/20 0.61
▸ TPH1 P17752 2/20 0.61
▸ GRB2 P62993 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL156189 1.00 SLC7A5 (0.74) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL93494 0.94 SLC7A5 (0.78) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL414363 0.94 SLC7A5 (0.78) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL180272 0.94 SLC7A5 (0.78) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL93495 0.94 SLC7A5 (0.78) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL1796036 0.94 SLC7A5 (0.78) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL2310526 0.93 SLC7A5 (0.83) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31369911 0.92 SLC7A5 (0.65) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL31369642 0.92 SLC7A5 (0.89) SLC7A5PTGS1ALPIPKMXIAP
Hydrochloric Acid SCHEMBL3695982 0.92 SLC7A5 (0.75) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240247034-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH INC (US) 2024-07-25 — — US claimed
EP-3169403-B9 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-07-03 — — EP claimed
EP-3169403-B1 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-02-14 — — EP claimed
CN-117241818-A Combination therapy of amuc_1100 and immune checkpoint modulator for the treatment of cancer 和度生物技术(上海)有限公司 2023-12-15 — — CN claimed
CN-116262133-A Polypeptide freeze-dried powder injection for injection and preparation method and application thereof 南京安吉生物科技有限公司 2023-06-16 — — CN claimed
CN-116262112-A Fusion polypeptide preparation for aerosol inhalation and preparation method and application thereof 南京安吉生物科技有限公司 2023-06-16 — — CN claimed
US-20230174596-A1 CYSTINE KNOT SCAFFOLD PLATFORM GENENTECH INC (US) 2023-06-08 — — US claimed
CN-114805528-A Cystine knot scaffold platform 豪夫迈·罗氏有限公司 2022-07-29 — — CN claimed
CN-114591422-A Cystine knot scaffold platform 豪夫迈·罗氏有限公司 2022-06-07 — — CN claimed
CN-113413466-A Combination therapy of AMUC 1100 and immune checkpoint modulator for the treatment of cancer 和度生物医药(上海)有限公司 2021-09-21 — — CN claimed
CN-103145855-B Matrix metallo-proteinase inhibitor polypeptide and application thereof NANJING ANJI BIOTECHNOLOGY CO LTD 2015-04-22 — — CN claimed
WO-2015048364-A1 RECOMBINANT CELLS AND ORGANISMS HAVING PERSISTENT NONSTANDARD AMINO ACID DEPENDENCE AND METHODS OF MAKING THEM PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-04-02 — — WO claimed
CN-104045718-A Multifunctional fused polypeptide as well as preparation method and application thereof NANJING ANJI BIOLOG SCIENCE & TECHNOLOGY CO LTD 2014-09-17 — — CN claimed
US-20050164949-A1 Antagonistic peptides of prostaglandin E2 receptor subtype EP4 THERATECHNOLOGIES INC. (CA) 2005-07-28 — — US claimed
EP-0950046-B1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS NAEJA PHARMACEUTICAL INC (CA) 2002-04-10 — — EP claimed
EP-1025127-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES Wapharm AB (SE) 2000-08-09 — — EP claimed
EP-0950046-A1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS SYNPHAR LABORATORIES INC. (CA) 1999-10-20 — — EP claimed
US-5959123-A REACATING SUBSTITUTED AMINO ACID WITH 3-AMINO-4-SUBSTITUTED-AZETIDINE-2-ONE COMPOUND TO FORM 3, 4-DISUBSTITUTED-AZETIDINE-2-ONE COMPOUND; USEFUL FOR TREATING MUSCULAR DYSTROPHY, ARTHRITIS, VIRAL AND PARASITIC INFECTIONS SYNPHAR LABORATORIES, INC. (CA) 1999-09-28 — — US claimed
WO-1998037097-A1 MSH-RECEPTOR SUBTYPE SELECTIVE CYCLIC PEPTIDES WAPHARM AB (SE) 1998-08-27 — — WO claimed
WO-1998012176-A1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS SYNPHAR LABORATORIES INC. (US) 1998-03-26 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240247034-A1 CYSTINE KNOT SCAFFOLD PLATFORM LRP6, LDLR, KDR SLC7A5 504/4885PTGS1 2821/4885ALPI 3665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.